Ligandal, today announces the positive results of laboratory studies that demonstrate the effectiveness of its synthetic peptide, SARS-BLOCK鈩�, as a combination treatment and vaccine to COVID-19.
The experiments, in conjunction with the Stroud Lab, University of California San Francisco, demonstrate SARS-BLOCK鈩� halts infection of SARS-CoV-2. In addition to being an effective inhibitor of infection, SARS-BLOCK鈩� has high affinity with neutralising antibodies, enabling it to enhance the immune response to the SARS-CoV-2 virus. The results mean SARS-BLOCK鈩� shows real promise as a combination treatment and vaccine.
Andre Watson, CEO and Founder of Ligandal, says, 鈥淥ur results so far have been very positive. We鈥檝e demonstrated SARS-BLOCK鈩� inhibits ACE2 cellular entry of the SARS-CoV-2 spike protein. We have also established that SARS-BLOCK鈩� prevents infection of ACE2-expressing cells by the virus. We鈥檙e grateful for the work Professor Stroud and his team have done in helping us understand the efficacy of SARS-BLOCK鈩�.鈥�
The experiments demonstrate that Ligandal鈥檚 novel genetic medicine approach has yielded a very promising therapy to COVID-19. Ligandal modelled its approach by addressing the specific microbiological characteristics of the virus, rather than repurposing existing technology. As such, the firm has met the threat of SARS-CoV-2 with a completely new, specifically tailored response that allowed it to develop a combination treatment and vaccine.
More from News
- Two Thirds of Brits Are Telling AI Chatbots Their Secrets But Don’t Trust The Companies Behind Them
- Video Game Companies Are Abandoning “Buy Our Console To Play This” 鈥� Here鈥檚 Why
- UK Gambling Operators Face New Deposit Limit Rules From 30 September
- How A Ransomware Gang Hijacked A Rival Gang鈥檚 Website 鈥� And Is Now Extorting Them For “2.333% Of Their Net Worth
- Meta Promised Unmatched Privacy For Muse 鈥� So How Did Researchers Crack It So Quickly?
- Digital Avatars Are Bringing Deceased Artists Back To The Stage 鈥� Where Do We Draw The Line?
- Can Europe Solve Its Critical Minerals Problem Fast Enough To Support Its Tech Ambitions?
- Google Has Agreed To A 拢260 Million Settlement: Who’s Eligible For Compensation?
Adam Hamdy, a medical industry consultant and author, who recently joined the company鈥檚 advisory board says, 鈥淭his is groundbreaking science. In 2007, Nobel Prize Winner Professor Rolf Zinkernagel hypothesised synthetic peptides could be used to inhibit viral infection and elicit an immune response. 13 years later, Ligandal鈥檚 synthetic peptide, SARS-BLOCK鈩�, appears to have done exactly that.鈥�
Andre Watson says, 鈥淭he next step is for us to test SARS-BLOCK鈩� in animals and humans. If trials of SARS-BLOCK鈩� prove successful, we expect to move to mass market manufacturing within 18 months. Our innovative, distributed manufacturing process means we will be able to respond to global demand very quickly.鈥�
Adam Hamdy says, 鈥淪ARS-BLOCK鈩� has significant advantages over other vaccines and therapies in development. It was designed to neutralise SARS-CoV-2 at a genetic level, and the results suggest it is effective at doing so. SARS-BLOCK鈩� is 100% room temperature stable and therefore can be easily deployed globally to any setting. We鈥檙e feeling very positive about both the cost and availability of the treatment.鈥�
